scholarly journals Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study

2021 ◽  
Author(s):  
Clément R. Massonnaud ◽  
Jonathan Roux ◽  
Vittoria Colizza ◽  
Pascal Crépey
Keyword(s):  
Booster Vaccination ◽  
Vaccination Strategies ◽  
Modeling Study

scholarly journals Combating pertussis resurgence: One booster vaccination schedule does not fit all

2015 ◽  
Vol 112 (5) ◽  
pp. E472-E477 ◽  
Author(s):  
Maria A. Riolo ◽  
Pejman Rohani
Keyword(s):  
Booster Vaccination ◽  
Cost Effective ◽  
Vaccination Schedule ◽  
Health Concern ◽  
Transmission Model ◽  
Public Health Concern ◽  
Vaccine Failure ◽  
Vaccination Strategies ◽  
Vaccine Booster ◽  
Pertussis Epidemiology

Pertussis has reemerged as a major public health concern in many countries where it was once considered well controlled. Although the mechanisms responsible for continued pertussis circulation and resurgence remain elusive and contentious, many countries have nevertheless recommended booster vaccinations, the timing and number of which vary widely. Here, using a stochastic, age-stratified transmission model, we searched for cost-effective booster vaccination strategies using a genetic algorithm. We did so assuming four hypothesized mechanisms underpinning contemporary pertussis epidemiology: (I) insufficient coverage, (II) frequent primary vaccine failure, (III) waning of vaccine-derived protection, and (IV) vaccine “leakiness.” For scenarios I–IV, successful booster strategies were identified and varied considerably by mechanism. Especially notable is the inability of booster schedules to alleviate resurgence when vaccines are leaky. Critically, our findings argue that the ultimate effectiveness of vaccine booster schedules will likely depend on correctly pinpointing the causes of resurgence, with misdiagnosis of the problem epidemiologically ineffective and economically costly.

scholarly journals Pertussis diagnosis in Belgium: results of the National Reference Centre for Bordetella anno 2015

2017 ◽  
Vol 145 (11) ◽  
pp. 2366-2373 ◽  
Author(s):  
H. MARTINI ◽  
C. RODEGHIERO ◽  
C. VAN DEN POEL ◽  
M. VINCENT ◽  
D. PIERARD ◽  
...  
Keyword(s):  
Acute Infection ◽  
Booster Vaccination ◽  
Infants And Children ◽  
Age Group ◽  
Limited Data ◽  
Serum Samples ◽  
Pertussis Infection ◽  
Vaccination Strategies ◽  
National Reference ◽  
Reference Centre

SUMMARYIn 2015, the Belgian National Reference Centre for Bordetella analyzed 4110 respiratory samples by qPCR and 4877 serum samples by serology. Whereas about 50% of respiratory samples were from infants and children below the age of five, serum samples were distributed among all age categories. A total of 394 (9·6%) cases was diagnosed as positive for Bordetella pertussis by qPCR and 844 (17·3%) cases were diagnosed as acute infection by serology (anti-pertussis toxin (PT) IgG > 125 IU/ml). Another 1042 (21·4%) sera had anti-PT IgG between 55 and 125 IU/ml reflecting a vaccination or pertussis infection during the last 1–2 years. Seventy per cent of the pertussis cases diagnosed by qPRC were in infants and children younger than 14 years old, whereas the highest number of sera with anti-PT levels >125 IU/ml was in the age group of 10–14 years old. Based on the limited data of the last vaccination (reported for only 15% of the samples), recent booster vaccination in the teenager group may have contributed only minimally to these elevated anti-PT levels. The highest number of sera with anti-PT titers between 55 and 125 IU/ml was found in the age category 50–59 years old. It is clear that pertussis continues to be a problem in Belgium and that other vaccination strategies (maternal vaccination, cocoon vaccination) and ultimately better vaccines will be needed to control this highly infectious respiratory disease.

HPV Screening and Vaccination Strategies in an Unscreened Population: A Mathematical Modeling Study

2018 ◽  
Vol 81 (11) ◽  
pp. 4313-4342 ◽  
Author(s):  
Rachael M. Milwid ◽  
Federico Frascoli ◽  
Marc Steben ◽  
Jane M. Heffernan
Keyword(s):  
Mathematical Modeling ◽  
Vaccination Strategies ◽  
Hpv Screening ◽  
Modeling Study

scholarly journals The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study

PLoS Medicine ◽  
2018 ◽  
Vol 15 (1) ◽  
pp. e1002495 ◽  
Author(s):  
Reza Yaesoubi ◽  
Caroline Trotter ◽  
Caroline Colijn ◽  
Maziar Yaesoubi ◽  
Anaïs Colombini ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Burkina Faso ◽  
Dynamic Modeling ◽  
Transmission Dynamic ◽  
Meningococcal Vaccines ◽  
Vaccination Strategies ◽  
The Cost ◽  
Modeling Study

scholarly journals Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants

2022 ◽  
Author(s):  
Arinjay Banerjee ◽  
Jocelyne Lew ◽  
Andrea Kroeker ◽  
Kaushal Baid ◽  
Patryk Aftanas ◽  
...  
Keyword(s):  
Clinical Specimen ◽  
Booster Vaccination ◽  
Neutralizing Antibody ◽  
Clinical Isolates ◽  
Spike Protein ◽  
Receptor Binding Domain ◽  
Vaccination Strategies ◽  
Antibody Titers ◽  
Ancestral Virus ◽  
Antibody Levels

The omicron variant of concern (VOC) of SARS-CoV-2 was first reported in November 2021 in Botswana and South Africa. Omicron variant has evolved multiple mutations within the spike protein and the receptor binding domain (RBD), raising concerns of increased antibody evasion. Here, we isolated infectious omicron from a clinical specimen obtained in Canada. The neutralizing activity of sera from 65 coronavirus disease (COVID-19) vaccine recipients and convalescent individuals against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron VOCs was assessed. Convalescent sera from unvaccinated individuals infected by the ancestral virus during the first wave of COVID-19 in Canada (July, 2020) demonstrated reduced neutralization against beta, delta and omicron VOCs. Convalescent sera from unvaccinated individuals infected by the delta variant (May-June, 2021) neutralized omicron to significantly lower levels compared to the delta variant. Sera from individuals that received three doses of the Pfizer or Moderna vaccines demonstrated reduced neutralization of both delta and omicron variants relative to ancestral SARS-CoV-2. Sera from individuals that were naturally infected with ancestral SARS-CoV-2 and subsequently received two doses of the Pfizer vaccine induced significantly higher neutralizing antibody levels against ancestral virus and all VOCs. Importantly, infection alone, either with ancestral SARS-CoV-2 or the delta variant was not sufficient to induce high neutralizing antibody titers against omicron. This data will inform current booster vaccination strategies and we highlight the need for additional studies to identify longevity of immunity against SARS-CoV-2 and optimal neutralizing antibody levels that are necessary to prevent infection and/or severe COVID-19.

scholarly journals Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice

2022 ◽  
Vol 19 (1) ◽  
Author(s):  
Shuo Song ◽  
Bing Zhou ◽  
Lin Cheng ◽  
Weilong Liu ◽  
Qing Fan ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Inactivated Vaccine ◽  
Wild Type ◽  
Broadly Neutralizing Antibodies ◽  
Vaccination Strategies ◽  
Inactivated Vaccines

AbstractThe current COVID-19 pandemic caused by constantly emerging SARS-CoV-2 variants still poses a threat to public health worldwide. Effective next-generation vaccines and optimized booster vaccination strategies are urgently needed. Here, we sequentially immunized mice with a SARS-CoV-2 wild-type inactivated vaccine and a heterologous mutant RBD vaccine, and then evaluated their neutralizing antibody responses against variants including Beta, Delta, Alpha, Iota, Kappa, and A.23.1. These data showed that a third booster dose of heterologous RBD vaccine especially after two doses of inactivated vaccines significantly enhanced the GMTs of nAbs against all SARS-CoV-2 variants we tested. In addition, the WT and variants all displayed good cross-immunogenicity and might be applied in the design of booster vaccines to induce broadly neutralizing antibodies.

scholarly journals A systematic approach to simultaneously evaluate safety, immunogenicity, and efficacy of novel tuberculosis vaccination strategies

2020 ◽  
Vol 6 (10) ◽  
pp. eaaz1767 ◽  
Author(s):  
Visai Muruganandah ◽  
Harindra D. Sathkumara ◽  
Saparna Pai ◽  
Catherine M. Rush ◽  
Roland Brosch ◽  
...  
Keyword(s):  
Systematic Approach ◽  
Booster Vaccination ◽  
Adverse Outcomes ◽  
Bacille Calmette Guerin ◽  
Preclinical Evaluation ◽  
Routes Of Administration ◽  
Vaccination Strategies ◽  
Multiple Measurements ◽  
Human Use ◽  
Simple Empirical Model

Tuberculosis (TB) is the deadliest infectious disease worldwide. Bacille-Calmette-Guérin (BCG), the only licensed TB vaccine, affords variable protection against TB but remains the gold standard. BCG improvement is focused around three strategies: recombinant BCG strains, heterologous routes of administration, and booster vaccination. It is currently unknown whether combining these strategies is beneficial. The preclinical evaluation for new TB vaccines is heavily skewed toward immunogenicity and efficacy; however, safety and efficacy are the dominant considerations in human use. To facilitate stage gating of TB vaccines, we developed a simple empirical model to systematically rank vaccination strategies by integrating multiple measurements of safety, immunogenicity, and efficacy. We assessed 24 vaccination regimens, composed of three BCG strains and eight combinations of delivery. The model presented here highlights that mucosal booster vaccination may cause adverse outcomes and provides a much needed strategy to evaluate and rank data obtained from TB vaccine studies using different routes, strains, or animal models.

scholarly journals Evaluating COVID-19 booster vaccination strategies in a partially vaccinated population: a modeling study.

2021 ◽  
Author(s):  
Clément Massonnaud ◽  
Jonathan Roux ◽  
Vittoria Colizza ◽  
Pascal Crépey
Keyword(s):  
Compartmental Model ◽  
Age Groups ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Effective Strategy ◽  
Younger Adults ◽  
Vaccination Strategies ◽  
Admission Data ◽  
Vaccination Campaigns ◽  
The Impact

Abstract Background. Several countries are implementing COVID-19 booster vaccination campaigns. The objective of this study was to model the impact of different primary and booster vaccination strategies. Methods. We used a compartmental model fitted to hospital admission data in France to analyze the impact of primary and booster vaccination strategies on morbidity and mortality, assuming waning of immunity and various levels of virus transmissibility during winter. Results. Strategies prioritizing primary vaccinations were systematically more effective than strategies prioritizing boosters. Regarding booster strategies targeting different age groups, their effectiveness varied with immunity and virus transmissibility levels. If waining of immunity affects all adults, people aged 30 to 49 years should be boosted in priority, even for low transmissibility levels. Discussion. Increasing the primary vaccination coverage should remain a priority. If a plateau has been reached, boosting immunity of younger adults could be the most effective strategy, especially if SARS-CoV-2 transmissibility is high.

Keeping Vulnerable Children Safe from Pertussis Preventing Nosocomial Pertussis Transmission in the Neonatal Intensive Care Unit

2009 ◽  
Vol 30 (11) ◽  
pp. 1084-1089 ◽  
Author(s):  
Amy L. Greer ◽  
David N. Fisman
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Neonatal Intensive Care Unit ◽  
Healthcare Workers ◽  
Neonatal Intensive Care ◽  
Booster Vaccination ◽  
The United States ◽  
Base Case ◽  
Vaccination Strategies ◽  
The Impact

Objective.To examine the impact of different acellular pertussis booster vaccination strategies on the probability of a nosocomial pertussis outbreak occurring and the distribution of outbreak sizes observed for each intervention strategy.Setting.Neonatal intensive care unit.Methods.We developed a stochastic, agent-based simulation model to examine the impact of booster vaccination strategies for pertussis on health care-related transmission.Results.Our results demonstrate that healthcare worker booster vaccination decreases the probability of secondary transmission from 49% (base case, no boosting) to 2% (if 95% of healthcare workers are boosted) and decreases final outbreak size. Boosting family caregivers did not have a clinically significant impact on nosocomial disease transmission.Conclusion.The provision of booster vaccine to healthcare workers in the neonatal intensive care unit substantially reduces the risk of hospital-centered pertussis outbreaks in a manner that enhances the health of hospitalized children. A formal health economic analysis of this finding is currently under way. Policies to protect patient safety in pediatric facilities should include compliance with the United States Advisory Committee on Immunization Practices, which recommends provision of pertussis booster vaccination to healthcare workers.

Sign in / Sign up

Export Citation Format

Share Document